Article Details
Retrieved on: 2021-04-01 14:15:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Longer term, Pfizer stock sports a 20% year-over-year lead. Analysts are still hesitant towards the equity, with nine of the 14 in coverage sporting a tepid ...
Article found on: www.schaeffersresearch.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here